Rigel Pharmaceuticals Financial Results
Rigel Pharmaceuticals reported Q3 2026 total revenues of $80.9 million, driven by $72.3 million in net product sales and the commercial launch of VEPPANU. The company achieved net income of $13.2 million for the quarter and updated its full-year 2026 revenue outlook to a range of $290 million to $295 million.
- Term
- Q3 2026
“VEPPANU’s launch marks an exciting and transformational milestone for Rigel and we are very pleased with the initial uptake. In the first six weeks of launch we shipped VEPPANU to more than 100 patients and clinics and have already seen many refills.”
Raul Rodriguez, Rigel’s president and CEO
“Our priorities are to build on the VEPPANU launch and advance R289 in lower-risk MDS, with updated Phase 1b data to be presented at ASH in December. We believe VEPPANU and R289 have significant commercial potential to further transform Rigel and drive long-term shareholder value.”
Raul Rodriguez, Rigel’s president and CEO